Cibc World Market Inc. Buys Shares of 33,153 Smith & Nephew SNATS, Inc. $SNN

Cibc World Market Inc. purchased a new position in Smith & Nephew SNATS, Inc. (NYSE:SNN) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 33,153 shares of the medical equipment provider’s stock, valued at approximately $2,079,000.

A number of other large investors also recently modified their holdings of SNN. Equity Investment Corp raised its stake in shares of Smith & Nephew SNATS by 3.9% during the fourth quarter. Equity Investment Corp now owns 7,502 shares of the medical equipment provider’s stock valued at $246,000 after purchasing an additional 285 shares in the last quarter. Smartleaf Asset Management LLC grew its position in Smith & Nephew SNATS by 13.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 2,820 shares of the medical equipment provider’s stock valued at $93,000 after buying an additional 334 shares in the last quarter. Cary Street Partners Financial LLC grew its position in Smith & Nephew SNATS by 1.8% in the 4th quarter. Cary Street Partners Financial LLC now owns 20,255 shares of the medical equipment provider’s stock valued at $665,000 after buying an additional 365 shares in the last quarter. Parallel Advisors LLC increased its stake in Smith & Nephew SNATS by 20.0% during the 1st quarter. Parallel Advisors LLC now owns 2,322 shares of the medical equipment provider’s stock valued at $74,000 after buying an additional 387 shares during the period. Finally, Clearstead Trust LLC acquired a new position in Smith & Nephew SNATS during the 2nd quarter valued at about $25,000. 25.64% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on SNN. Weiss Ratings downgraded Smith & Nephew SNATS from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, June 11th. Sanford C. Bernstein set a $31.85 price objective on Smith & Nephew SNATS in a research note on Monday, May 11th. Morgan Stanley restated an “overweight” rating on shares of Smith & Nephew SNATS in a report on Wednesday, August 5th. Zacks Research cut Smith & Nephew SNATS from a “hold” rating to a “strong sell” rating in a research note on Friday, August 7th. Finally, Barclays lowered Smith & Nephew SNATS from an “equal weight” rating to an “underweight” rating in a report on Wednesday, August 5th. Two research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Smith & Nephew SNATS has a consensus rating of “Hold” and a consensus price target of $30.93.

Smith & Nephew SNATS Stock Up 0.3%

Smith & Nephew SNATS stock opened at $29.32 on Thursday. Smith & Nephew SNATS, Inc. has a fifty-two week low of $28.56 and a fifty-two week high of $38.79. The firm’s 50 day simple moving average is $30.26 and its 200-day simple moving average is $31.74. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.14 and a quick ratio of 1.11.

Smith & Nephew SNATS Dividend Announcement

The company also recently disclosed a dividend, which will be paid on Friday, November 6th. Shareholders of record on Friday, October 2nd will be given a dividend of $0.312 per share. This represents a yield of 205.0%. The ex-dividend date is Friday, October 2nd.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.